Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18203900 | 1.00 | HRH4 (0.33) | HRH4 | |
| SCHEMBL26134382 | 1.00 | HRH4 (0.33) | HRH4 | |
| SCHEMBL30419630 | 1.00 | HRH4 (0.33) | HRH4 | |
| SCHEMBL16043980 | 1.00 | HRH4 (0.33) | HRH4 | |
| SCHEMBL29384130 | 0.86 | HRH4 (0.36) | HRH4 | |
| SCHEMBL15817410 | 0.85 | HRH4 (0.32) | HRH4 | |
| SCHEMBL31200544 | 0.85 | PADI4 (0.36) | HRH4 | |
| SCHEMBL18203968 | 0.85 | HRH4 (0.32) | HRH4 | |
| SCHEMBL18203969 | 0.85 | HRH4 (0.32) | HRH4 | |
| SCHEMBL24855450 | 0.84 | CHRNB2 (0.40) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-20230002408-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| EP-3807271-A1 | PYRIDINYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| EP-3802539-A1 | TETRAHYDRO-1 H-PYRAZINO[2,1 -AJISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016016316-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2016-02-04 | — | — | WO | disclosed |
| EP-2518079-A2 | HCV/HIV inhibitors and their uses | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-7592335-B2 | Oxazolidinone derivatives as antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-22 | — | — | US | disclosed |
| US-20080188470-A1 | Oxazolidinone Derivatives as Antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| EP-1874782-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006109156-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188470-A1 | Oxazolidinone Derivatives as Antimicrobials | PDK4, SDHA, OXA1L | HRH4 3015/4885 |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | HRH4 3895/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HRH4 3238/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | HRH4 3345/4885 |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | HRH4 319/4885 |
| US-20230002408-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | HRH4 1762/4885 |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | HRH4 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.